PPD, Inc., a leading global contract research organization (CRO), recently held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies.

The 67,000-square-foot facility in the Suzhou New District, Jiangsu Province, offers bioanalytical, biomarker and vaccine laboratory services to support trials across all phases of pharmaceutical development.

The company anticipates adding approximately 300 highly skilled professionals over the next three years as a result of the expansion. This new lab supplements the company’s existing Shanghai central lab, established in 2015.

The lab encompasses multiple technology platforms across a wide range of applications, including ligand-binding immunochemistry, liquid chromatography tandem mass spectrometry (LC-MS/MS), polymerase chain reaction (PCR) and flow cytometry.

The lab also specializes in the development and validation of fully compliant robust custom assays for pharmacokinetic/pharmacodynamic (PK/PD) analyses and immunogenicity assessments in both preclinical and clinical studies.

In the Asia-Pacific region, PPD also maintains central labs in Shanghai and Singapore that provide support for global clinical trials with safety and efficacy testing, custom specimen collection kits and sample management services.